|Articles|September 1, 2004
- Pharmaceutical Executive-09-01-2004
September Table of Contents
September Table of Contents
Advertisement
Articles in this issue
almost 22 years ago
September Table of Contentsalmost 22 years ago
(Huge) Untapped Opportunityalmost 22 years ago
Information Into Actionalmost 22 years ago
Halting the Hypealmost 22 years ago
Spend Trends: A $20 Billion Bill and Plenty of Changealmost 22 years ago
From the Mouths of Babesalmost 22 years ago
Safe and Securealmost 22 years ago
Synta's Surprisealmost 22 years ago
The New Building Blocks for Blockbustersalmost 22 years ago
Specialty Therapies Lose Special StatusAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The New Healthy Aging Imperative and What It Means for Pharma
2
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
3
Reading Between the Lines: Closing the T1D Misdiagnosis Gap
4
Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It
5